COMP <GO>
RIGL vs ABBV // FREE CASH FLOW YIELD
Rigel Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RIGL 6
— ABBV 5
▲ FREE CASH FLOW YIELD LEADER: RIGL
LAST: $51.45 (+1.40%) • MKT CAP: $961.1M
fcf-yield
7.87%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RIGL VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RIGL | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.30% | 70.20% | +23.10 | RIGL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.20% | 29.00% | -0.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.3x | 33.3x | -26.00 | RIGL | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 7.87% | 3.47% | +4.40 | RIGL | /fcf-yield <GO> |
| Operating Margin | 42.60% | 24.60% | +18.00 | RIGL | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 6.90% | +61.10 | RIGL | /net-margins <GO> |
| Revenue Growth (YoY) | 64.10% | 8.60% | +55.50 | RIGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.64 | 5.33 | -1.69 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.4 | 65.1 | -0.72 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $961.1M | $513.86B | -$512.90B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RIGL REV | ABBV REV | RIGL GROSS % | ABBV GROSS % | RIGL FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $294.3M | $61.16B | 93.3% | 70.2% | $75.7M | $17.82B |
| FY 2024 | $179.3M | $56.33B | 89.6% | 70.0% | $31.5M | $17.83B |
| FY 2023 | $116.9M | $54.32B | — | — | -$5.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RIGL // BETA —
ABBV // BETA 1.15